Ranbaxy Laboratories soars on reporting consolidated net profit of Rs 477.76 crore in Q2FY15

28 Oct 2014 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 641.00, up by 43.40 points or 7.26% from its previous closing of Rs. 597.60 on the BSE.

The scrip opened at Rs. 600.00 and has touched a high and low of Rs. 642.60 and Rs. 600.00 respectively. So far 719812 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 667.30 on 03-Sep-2014 and a 52 week low of Rs. 306.05 on 27-Jan-2014.

Last one week high and low of the scrip stood at Rs. 642.60 and Rs. 586.55 respectively. The current market cap of the company is Rs. 26752.34 crore.

The promoters holding in the company stood at 63.37% while Institutions and Non-Institutions held 21.49% and 13.73% respectively.

Ranbaxy Laboratories has reported a net loss of Rs 368.26 crore for the quarter under review as compared to a net loss of Rs 842.23 crore for the same quarter in the previous year. Total income of the company has decreased 8.92% at Rs 1338.93 crore for Q2FY15 as compared Rs 1470.19 crore for the corresponding quarter previous year.

On consolidated basis, the company has posted a net profit after taxes and minority interest of Rs 477.76 crore for the quarter as against a net loss of Rs 454.17 crore in the September quarter of previous fiscal. The company’s total income has increased by 15.92% at Rs 3277.88 crore for the quarter from Rs 2827.73 crore in the similar quarter of previous year.

Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.